🔴 NeoGenomics is trading 5% down today on profit-taking after FDA-approved diagnostic launch

NeoGenomics is trading 5% down at $13.99 as shares pull back following the initial market reaction to its latest FDA approval.

• The company launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma and AstraZeneca’s TRUQAP therapy.
• Despite the potential for long-term revenue growth from the test, the stock is seeing company-specific profit-taking while major indices trend modestly higher.